ProCE Banner Activity

Phase II Study Results of Lenacapavir, Teropavimab, and Zinlirvimab for People Living with Virologically Suppressed HIV

Conference Coverage
Slideset

Phase II data suggest that, in people living with HIV-1 highly susceptible to both antibodies, virologic suppression can be maintained with combination of lenacapavir plus broadly neutralizing antibodies teropavimab and zinlirvimab.

Released: March 14, 2025

Expiration: September 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare